Applies to fosfomycin: oral powder for solution.
Serious side effects of Fosfomycin
Along with its needed effects, fosfomycin may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking fosfomycin:
Rare
- Blood in the urine
- burning while urinating
- cough or hoarseness
- difficult or painful urination
- fever or chills
- lower back or side pain
- painful or difficult urination
Incidence not known
- Abdominal or stomach pain or tenderness
- black, tarry stools
- bloating
- chest pain
- clay-colored stools
- constipation
- dark urine
- diarrhea
- difficulty with swallowing
- dizziness
- fast heartbeat
- headache
- hives
- itching
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
- light-colored stools
- loss of appetite
- nausea or vomiting
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- rash
- severe abdominal or stomach cramps and pain
- shortness of breath
- sores, ulcers, or white spots on the lips or in the mouth
- swollen or painful glands
- tightness in the chest
- unpleasant breath odor
- unusual bleeding or bruising
- unusual tiredness or weakness
- vomiting of blood
- watery and severe diarrhea, which may also be bloody
- wheezing
- worsening of asthma
- yellow eyes or skin
Other side effects of Fosfomycin
Some side effects of fosfomycin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Itching of the vagina or genital area
- pain during sexual intercourse
- thick, white vaginal discharge with no odor or with a mild odor
Less common
- Acid or sour stomach
- back pain
- belching
- body aches or pain
- congestion
- dryness or soreness of the throat
- heartburn
- heavy bleeding
- indigestion
- lack or loss of strength
- pain
- painful menstruation
- runny or stuffy nose
- skin rash
- sneezing
- sore throat
- stomach discomfort or upset
- tender, swollen glands in the neck
- trouble with swallowing
- voice changes
- weakness
Rare
- Abnormal stools
- absent missed or irregular menstrual periods
- blindness
- blue-yellow color blindness
- blurred vision
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- decreased vision
- difficulty with moving
- dry mouth
- excess air or gas in the stomach or intestines
- eye pain
- full feeling
- headache, severe and throbbing
- joint pain
- loss of appetite
- muscle aching or cramping
- muscle pains or stiffness
- nervousness
- passing gas
- sleepiness or unusual drowsiness
- sleeplessness
- stopping of menstrual bleeding
- swollen joints
- swollen, painful, or tender lymph glands in the neck, armpit, or groin
- trouble sleeping
- unable to sleep
- weight loss
Incidence not known
- Hearing loss
For Healthcare Professionals
Applies to fosfomycin: oral granule for reconstitution, oral powder for reconstitution.
Gastrointestinal
Very common (10% or more): Diarrhea (up to 10.4%)
Common (1% to 10%): Nausea, abdominal pain, dyspepsia, retching, stomach ache
Uncommon (0.1% to 1%): Abnormal stools, constipation, dry mouth, flatulence, vomiting
Frequency not reported: Pseudomembranous colitis
Postmarketing reports: Toxic megacolon, antibiotic-associated colitis, oral paresthesias (temporary tingling of mouth, tongue, cheek)[Ref]
Nervous system
Very common (10% or more): Headache (up to 10.3%)
Common (1% to 10%): Dizziness
Uncommon (0.1% to 1%): Dysgeusia, paresthesia, migraine, somnolence, vertigo
Postmarketing reports: Hearing loss, temporary alterations of taste (dysgeusia, hypogeusia)[Ref]
Genitourinary
Common (1% to 10%): Vaginitis, dysmenorrhea, vulvovaginitis
Uncommon (0.1% to 1%): Hematuria, dysuria, menstrual disorder[Ref]
Other
Common (1% to 10%): Pain, asthenia, injection site phlebitis
Uncommon (0.1% to 1%): Fatigue, infection, ear disorder, fever, influenza syndrome
Frequency not reported: Facial edema[Ref]
Hypersensitivity
Very rare (less than 0.01%): Anaphylactic shock
Postmarketing reports: Anaphylaxis, anaphylactic reactions (including anaphylactic shock), hypersensitivity[Ref]
Respiratory
Common (1% to 10%): Rhinitis, pharyngitis
Uncommon (0.1% to 1%): Dyspnea
Frequency not reported: Asthmatic attack
Postmarketing reports: Asthma, exacerbation of asthma[Ref]
Dermatologic
Angioedema has also been reported during postmarketing experience.[Ref]
Common (1% to 10%): Rash
Uncommon (0.1% to 1%): Pruritus, skin disorder, urticaria
Frequency not reported: Angioedema[Ref]
Musculoskeletal
Common (1% to 10%): Back pain
Uncommon (0.1% to 1%): Myalgia[Ref]
Metabolic
Uncommon (0.1% to 1%): Anorexia, decreased appetite, hypernatremia and/or hypokalemia, increased alkaline phosphatase[Ref]
Increased alkaline phosphatase was generally transient and not clinically significant.[Ref]
Hematologic
Uncommon (0.1% to 1%): Lymphadenopathy
Rare (0.01% to 0.1%): Aplastic anemia, eosinophilia
Frequency not reported: Agranulocytosis, granulocytopenia, leukopenia, pancytopenia, thrombocytopenia, increased eosinophil count, increased or decreased white blood cell count, increased and decreased platelet count, decreased hematocrit, decreased hemoglobin[Ref]
Increased eosinophil count, increased or decreased white blood cell count, increased and decreased platelet count, decreased hematocrit, and decreased hemoglobin were generally transient and not clinically significant.
Aplastic anemia has also been reported during postmarketing experience.[Ref]
Hepatic
Fatty liver was completely reversible after IV fosfomycin was discontinued.
Increased bilirubin, increased ALT, and increased AST were generally transient and not clinically significant.[Ref]
Uncommon (0.1% to 1%): Increased ALT, increased AST
Very rare (less than 0.01%): Fatty liver
Frequency not reported: Increased bilirubin, hepatitis, cholestatic hepatitis, icterus
Postmarketing reports: Cholestatic jaundice, hepatic necrosis[Ref]
Cardiovascular
Uncommon (0.1% to 1%): Tachycardia
Postmarketing reports: Hypotension[Ref]
Psychiatric
Uncommon (0.1% to 1%): Insomnia, nervousness
Frequency not reported: Confusion[Ref]
Ocular
Very rare (less than 0.01%): Visual impairment
Frequency not reported: Unilateral optic neuritis[Ref]